Neupogen, Filgrastim Newswire

Neupogen, Filgrastim Newswire

Comprehensive Real-Time News Feed for Neupogen, Filgrastim (generic).

Results 1 - 20 of 82 in Neupogen, Filgrastim (generic)

  1. Dr Aimee Tharaldson Discusses Key Market Trends in Specialty PharmacyRead the original story w/Photo

    3 hrs ago | The American Journal of Managed Care

    There is a lot of competition in specialty pharmacy right now, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts. There is a lot of competition in specialty pharmacy right now, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.

    Comment?

  2. Amgen v. Adello: A Blind Biosimilar Infringement LawsuitRead the original story w/Photo

    Tuesday Apr 10 | JD Supra

    Last month, Amgen sued Adello Biologics, a US-based biosimilar maker, for patent infringement under the Biologics Price Competition and Innovation Act of 2009 in connection with Adello's proposed biosimilar of Amgen's Neupogen . Adello elected to bypass the pre-suit procedures of the BPCIA and did not provide any information to Amgen regarding its biosimilar or how it is manufactured.

    Comment?

  3. Amgen (AMGN) Receives Media Sentiment Score of 0.15Read the original story w/Photo

    Monday Apr 9 | IntersportsWire

    Press coverage about Amgen has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time.

    Comment?

  4. Reviewing AmgenRead the original story w/Photo

    Monday Apr 9 | AmericanBankingNews.com

    Amgen and Neuralstem are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership. Amgen pays an annual dividend of $5.28 per share and has a dividend yield of 3.1%.

    Comment?

  5. HPV patient documents first half of his gruelling chemo sessionsRead the original story w/Photo

    Saturday Mar 31 | Daily Mail

    Diary of HPV Patient: PAUL YOUNGER documents first half of his gruelling chemo and radiotheraphy sessions after tonsillar throat cancer diagnosis Paul Younger, 53, an NHS procurement manager and father-of-two from South-East London , was diagnosed with tonsillar throat cancer caused by HPV in January. oday The Mail on Sunday publishes the first instalment of his searing personal diary, detailing his gruelling chemo and radiotheraphy sessions - and the devastating effect they have had on his lifea I'm on my way to Guy's Hospital with my partner Helen before my treatment begins, feeling apprehensive.

    Comment?

  6. Filgrastim and Pegfilgrastim Litigation UpdatesRead the original story w/Photo

    Wednesday Mar 28 | JD Supra

    Over the past several weeks, there have been numerous developments in U.S. patent litigation activity relating to biosimilars of Neupogen and Neulasta . Below is a summary of these developments.

    Comment?

  7. Oncobiologics Appoints Dr. Joerg Windisch to Board of DirectorsRead the original story

    Tuesday Mar 27 | Customer Interaction Solutions

    Oncobiologics, Inc. today announced the appointment of Joerg Windisch, Ph.D. to its board of directors, effective March 23, 2018. In addition, Oncobiologics announced the resignation of Yezan Haddadin as director and member of the board of director's Audit Committee.

    Comment?

  8. BPCIA Litigation RoundupRead the original story w/Photo

    Monday Mar 26 | jdsupra.com

    Below is our first quarter update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our previous quarterly updates by not providing its application and manufacturing information within 20 days of FDA acceptance as "required" under the first step of the patent dance set forth in subsection of the BPCIA, and by providing a purported notice of commercial marketing under subsection of BPCIA before FDA had approved the application.

    Comment?

  9. Montana student inspires man to donate bone marrowRead the original story w/Photo

    Mar 24, 2018 | Washington Times

    Giebink , 21, a premed student in his fourth year at Rocky Mountain College, flew to Denver to donate peripheral blood stem cells for a bone marrow transplant. He doesn't know the identity of the recipient.

    Comment?

  10. Cu Rotc student helping save a live -Read the original story w/Photo

    Mar 22, 2018 | Xenia Daily Gazette

    In a few weeks, a woman with a rare form of leukemia will have a second chance at life due to a Cedarville University student donating his bone marrow stem cells. Back in August, Andy Arreguin, an ROTC sophomore pre-law major from Kentucky, joined a stem cell donation directory inspired by the experiences of Dr. Jeff Haymond, dean of the Cedarville University school of business, who had donated stem cells to a young girl in Australia.

    Comment?

  11. Biosimilar Industry Demand, Market Scope, Growth Analysis, Research Forecasting 2018Read the original story

    Mar 12, 2018 | SBWire

    Biosimilar Market By Product ,Types , Application , Manufacturing , End User , Geography is a biologic medical product that ispractically an identical copy of an original product that is man-made.Biosimilars are made only when the patent for the original product gets expired.Guidelines for biosimilars play a major role in retaining the viability and stability between original and biosimilars products. Numerous regulatory authorities which includeEMA and FDA actively regulate the biosimilars commercialization and development.

    Comment?

  12. ASCO Issues Statement on Use of Biosimilars in OncologyRead the original story w/Photo

    Feb 22, 2018 | JD Supra

    The American Society of Clinical Oncology recently issued a statement on use of biosimilars in oncology. According to ASCO, "[a]s many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer."

    Comment?

  13. Amgen (AMGN) and Adamis Pharmaceuticals (ADMP) Critical ReviewRead the original story w/Photo

    Feb 14, 2018 | IntersportsWire

    Amgen and Adamis Pharmaceuticals are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability. Amgen has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

    Comment?

  14. Biosimilars UpdateRead the original story w/Photo

    Jan 31, 2018 | The American Journal of Managed Care

    Multiple studies were presented at the American Society of Hematology Annual Meeting in Atlanta, Georgia last year that provided updates on the progress, use, and potential cost-savings of biosimilars. Kelly Davio In research presented at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, Noah Federman, MD, evaluated the safety and e cacy of subcutaneous tbo- lgrastim in pediatric patients undergoing chemotherapy for solid tumors.1 Chemotherapy-induced neutropenia, a common adverse event , can limit optimal dosing and treatment.

    Comment?

  15. No State Law Remedies for Failure to Comply with BPCIA NoticeRead the original story w/Photo

    Jan 29, 2018 | JD Supra

    On remand from the Supreme Court of the United States, the US Court of Appeals for the Federal Circuit held that under the Biologics Price Competition and Innovation Act of 2009 , state law claims and remedies are not available in biosimilar patent litigation. Amgen Inc. v.

    Comment?

  16. Market Research on Febrile Neutropenia Market 2014 and Analysis to 2020Read the original story w/Photo

    Jan 24, 2018 | SBWire

    Febrile neutropenia is defined as the development of fever with the sign of infection. Febrile neutropenia is one of the most severe complications of cancer chemotherapy and is mainly caused by infectious agents like gram-positive and gram-negative bacteria.

    Comment?

  17. Biosimilar 2017: Increasing Demand and Global Industry Current Scenario 2024Read the original story w/Photo

    Jan 19, 2018 | SBWire

    Biosimilar Market By Product ,Types , Application , Manufacturing , End User , Geography Global Industry Trends and Forecast to 2024 The Global Biosimilar Market accounted to USD 3.5 billion in 2016 growing at a CAGR of 27.0% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

    Comment?

  18. State Law Cannot Circumvent Congress's Scheme for BiologicsRead the original story w/Photo

    Jan 11, 2018 | JD Supra

    In Amgen v. Sandoz , No. 2015-1499 , the Federal Circuit affirmed the Northern District of California's decision that Sandoz had not waived its preemption defense and that the Biologics Price Competition and Innovation Act of 2009 preempted Amgen's state law claims against Sandoz's abbreviated biologics license application for filgrastim .

    Comment?

  19. Recombinant Therapeutic Antibodies & Proteins Market to See Incredible Growth During 2015 - 2023Read the original story w/Photo

    Jan 3, 2018 | SBWire

    Increasing investment on research activities and introduction of new protein therapeutics has significantly contributed in growth and development of Recombinant Therapeutic Antibodies and Proteins Market. Moreover rising number of clinical trials in pharmaceutical industry have also contributed in growth and development of market in past few years.

    Comment?

  20. 5 myths about bone marrow donationsRead the original story

    Jan 1, 2018 | KCRA-TV Sacramento

    WEBVTT FIGHT THE DISEASE.BRIAN: SIX YEARS AGO, DR. JASONSOLOMON WENT FROM BEING APHYSICIAN TO BEING A PATIENTAFTER BEING DIAGNOSED WITHMYELODYSPLASIA, WHICH IS APRE-CANCER DISORDER.>> IT WAS A BIT OF SHOCK, AND IFELT FINE.I HAD ABSOLUTELY NO SYMPTOMS ATALL.BRIAN: WITHIN A YEAR ITDEVELOPED INTO LEUKEMIA, ANDJASON NEEDED A STEM CELLTRANSPLANT.>> THAT'S WHEN WE GOT INVOLVEDWITH THE BE THE MATCH PROGRAM.BRIAN: AS A PHYSICIAN, JASONKNEW A LOT ABOUT MEDICINE, BUTHE HAD DO SOME QUICK RESEARCH ONBONE MARROW DONORS AND THE ODDSOF FINDING A MATCH.>> I KNEW VERY LITTLE OF THEPROCESS.IT'S NOT MY FIELD OF MEDICINEAND I HAD NEVER INTERFACEDDIRECTLY WITH PATIENTS LIKETHIS.SO, THE CONCERN OF COURSE ISTHAT YOU'RE NOT GOING TO FIND AMATCH.IT'S STILL VERY RAW FOR ME.BRIAN: IT WAS A JEWISH CHAPLINWHO CONVINCED JASON EVERYTHINGWOULD WORK OUT.>> HE OFFERED US A MENORAH ANDWISHED US A HAPPY HOLIDAY ANDASSURED ... (more)

    Comment?